2. Immunology/Inflammation Stem Cell/Wnt MAPK/ERK Pathway NF-κB
  3. IRAK Toll-like Receptor (TLR) ERK NF-κB Interleukin Related
  4. BMS-986126

BMS-986126 is a potent, selective, and orally active IRAK4 inhibitor (IC50 = 5.3 nM). BMS-986126 broadly inhibits MyD88-dependent signaling pathways. BMS-986126 demonstrates robust activity in the MRL/lpr and NZB/NZW murine models of lupus, inhibiting multiple pathogenic responses. BMS-986126 can be used for autoimmune diseases research, such as lupus erythematosus (SLE).

Para uso exclusivo en investigación. No vendemos a pacientes.

BMS-986126

BMS-986126 Estructura química

No. CAS : 1610017-20-3

Tamaño Stock
50 mg   Obtener un presupuesto  
100 mg   Obtener un presupuesto  
250 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

BMS-986126 Related Antibodies

Top Publications Citing Use of Products

Ver todos los productos específicos de isoformas IRAK:

Ver todas las isoformas
IRAK1 IRAK3 IRAK4

Ver todos los productos específicos de isoformas Toll-like Receptor (TLR):

Ver todas las isoformas
TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

Ver todos los productos específicos de isoformas ERK:

Ver todas las isoformas
ERK ERK1 ERK2 ERK5 ERK8

Ver todos los productos específicos de isoformas NF-κB:

Ver todas las isoformas
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

Ver todos los productos específicos de isoformas Interleukin Related:

Ver todas las isoformas
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

BMS-986126 is a potent, selective, and orally active IRAK4 inhibitor (IC50 = 5.3 nM). BMS-986126 broadly inhibits MyD88-dependent signaling pathways. BMS-986126 demonstrates robust activity in the MRL/lpr and NZB/NZW murine models of lupus, inhibiting multiple pathogenic responses. BMS-986126 can be used for autoimmune diseases research, such as lupus erythematosus (SLE)[1].

IC50 & Target[1]

IRAK4

5.3 nM (IC50)

Cellular Effect
Cell Line Type Value Description References
PBMC IC50
0.048 μM
Compound: 28
Inhibition of lipoteichoic acid-induced IL6 production in human PBMC incubated for 30 mins by ELISA method
Inhibition of lipoteichoic acid-induced IL6 production in human PBMC incubated for 30 mins by ELISA method
[PMID: 25479567]
In Vitro

BMS-986126 demonstrates similar, nanomolar potency (IC50: 135-456 nM) against multiple MyD88-dependent TLRs (TLR2/5/7/9) in human PBMCs, as well as potent inhibition of both NF-κB-regulated (IL-6) and type I IFN (IFN-α) responses, extending to cytokines induced by IL-1β and IL-18[1].
BMS-986126 fails to significantly affect cytokine production induced by the MyD88-independent agonists TLR3 and TNF-α[1].
BMS-986126 (0-2 μM, 30 min) dose-dependently inhibits the phosphorylation of IKKα/β and ERK downstream of TLR2 and TLR4, and ERK downstream of TLR7 in human PBMCs[1].
BMS-986126 demonstrates equivalent potency in inhibiting TLR7/9-induced interferon response gene expression (e.g., IFIT1) in PBMCs from both healthy donors and patients with SLE[1].
BMS-986126 (5 μM, 30 min) broadly reverses the gene expression profile induced by TLR7 activation in human PBMCs, with a significant proportion of the inhibited genes being canonical interferon-stimulated genes[1].
BMS-986126 (16-80 nM, 30 min) exhibits a synergistic effect with Prednisolone (HY-17463) in suppressing TLR9-induced and flu virus-induced IFIT1 expression in human PBMCs, showing significantly greater inhibition than either single agent[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BMS-986126 Related Antibodies

Western Blot Analysis[1]

Cell Line: PBMCs
Concentration: 0, 0.07, 0.22, 0.67, 2 μM
Incubation Time: 30 min
Result: Inhibited LPS-induced IKKα/b and ERK phosphorylation.
Inhibited TLR2-induced IKKα/b and ERK phosphorylation.
Robustly inhibit Gardiquimod (HY-103697)-induced ERK phosphorylation
In Vivo

BMS-986126 (0.1-3 mg/kg, p.o., single dose 30 min pre-LTA/CpG-ODN/Gardiquimod) inhibits cytokine production downstream of multiple MyD88-dependent TLRs (TLR2/7/9) in mice[1].
BMS-986126 (0.3-10 mg/kg, p.o., daily for 6 days or 8 weeks) significantly inhibits disease activity in both spontaneous (MRL/lpr and NZB/NZW) murine lupus models[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female BALB/c mice intraperitoneally injected with LTA (25 mg/kg)[1]
Dosage: 0.1, 0.3, 1.0, and 3.0 mg/kg
Administration: p.o., single dose 30 min pre-LTA
Result: Dose-dependently suppressed LTA-induced IL-6 plasma levels, with maximal inhibition observed at the top dose of 3 mg/kg.
Animal Model: Male C57BL/6 mice (12-week-old) intravenously injected with CpG-ODN (2.5 μg)[1]
Dosage: 1 and 3 mg/kg
Administration: p.o., single dose 30 min pre-CpG-ODN
Result: Strongly suppressed IFN-α at both 2 and 8 h after CpG-ODN challenge.
No IFN-α was detected in any group at 24 h after CpG-ODN challenge.
Animal Model: Male C57BL/6 mice (12-week-old) intraperitoneally injected with Gardiquimod (5 mg/kg)[1]
Dosage: 1 and 3 mg/kg
Administration: p.o., single dose 30 min pre-Gardiquimod
Result: Dose-dependently suppressed both IFN-α and IL-6 production at both 2 and 8 h after Gardiquimod challenge.
Animal Model: Male MRL/lpr mice (12-14 weeks old)[1]
Dosage: 0.3, 1, 3, and 10 mg/kg
Administration: p.o., daily for 8 weeks
Result: Dose-dependently suppressed biomarkers of kidney damage and systemic inflammation.
Showed very strong inhibition of kidney damage end points, including reduction of absolute protein levels in the urine, urine NGAL levels, and serum blood urea nitrogen.
Demonstrated significant protection of all end points at 1 mg/kg.
Dose-dependently suppressed dsDNA-specific autoantibody titers, as well as plasma levels of IL-10 and IL-12p40.
Significantly suppressed the percentage of splenic IFN-α+ pDCs at both the 1 and 10 mg/kg doses.
Suppressed IL-6 production by splenic CD11b+ myeloid cells.
All but the lowest dose inhibited IgG deposition in the kidney.
Dose-dependently suppressed histopathology in the kidney.
Animal Model: Male C57BL/6 mice induced by Imiquimod (HY-B0180)[1]
Dosage: 0.3, 1, 3, and 10 mg/kg
Administration: p.o., daily for 6 days
Result: Dose-dependently suppressed skin thickening, scaling, erythema, and spleen weight gain.
Significantly inhibited skin histopathology at 3 and 10 mg/kg.
Maintained its plasma levels above the mouse in vitro whole blood LTA-induced IL-6 IC50 value for 24 h.
Maintained its concentrations above the mouse whole blood IC50 value (LTA-induced IL-6 IC50) for 8-12 h out of the day.
Animal Model: Female NZB/NZW mice (12-14 weeks old)[1]
Dosage: 0.3, 1, 3, and 10 mg/kg
Administration: p.o., daily for 25 weeks
Result: Strongly suppressed biomarkers of kidney damage at all doses tested, including urine protein levels and urine levels of NGAL.
Dose-dependently suppressed systemic end points including dsDNA-specific autoantibody titers and plasma IL-12p40 levels.
Inhibited the percentage of splenic IFN-α+ pDCs.
Significantly inhibited the expression of the IFN response gene IFIT1 in peripheral blood.
Dose-dependently inhibited IgG deposition in the kidney.
Significantly suppressed histopathology in the kidneys with profound effects on glomerular damage and tubular damage subscores.
Peso molecular

424.47

Fòrmula

C22H25FN6O2
No. CAS
SMILES

CC(C)(O)[C@H](F)CNC(C(C(NC1CC1)=C2)=CN=C2NC3=NC4=C(C=NC=C4)C=C3)=O
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BMS-986126 Related Classifications

  • Calculadora de molaridad

  • Calculadora de dilución

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BMS-9861261610017-20-3BMS986126BMS 986126IRAKToll-like Receptor (TLR)ERKNF-κBInterleukin RelatedInterleukin-1 receptor associated kinaseIL-1R associated kinaseExtracellular signal regulated kinasesNuclear factor-κBNuclear factor-kappaBILIRAK4MyD88-dependentMRL/lprNZB/NZWSLETLRIFN-αIL-6Inhibitorinhibitorinhibit

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

  

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

      

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
BMS-986126
Cat. No.:
HY-124995
Cantidad:
MCE Japan Authorized Agent:

Revisión del cliente

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nombre del producto

  

Lot #

Nombre del solicitante *

 

Direcciòn del E-mail *

Número de teléfono

 

Department *

Nombre de la Organizaciòn *

 

Country or Region *

Observaciones

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.